GET DAILY SIGNALSAvantor (AVTR) Returns to Organic Growth in Q3 2026
Key Takeaways
- Avantor (AVTR) reported third-quarter 2026 net sales of $1.70 billion, up 4.6% year over year, with organic growth of 5.2%.
- Adjusted earnings per share (EPS) came in at $0.22, ahead of the $0.21 Wall Street consensus, while GAAP diluted EPS was $0.30.
- Both core segments returned to organic growth, led by a 5.8% gain in VWR Distribution & Services and a 3.6% increase in Bioscience & Medtech Products (BMP).
- Management raised full-year 2026 guidance for organic revenue growth, adjusted EPS, and free cash flow, citing accelerating demand and execution gains.
- Despite the beat and raised outlook, shares slipped roughly 2.5% in early trading as investors weighed ongoing margin pressures.
Earnings Context and Why It Matters
Avantor (AVTR), a leading life science tools and services provider, has spent the past year working through its "Revival" transformation program after a prolonged stretch of declining organic revenue. The third quarter of 2026 represents a meaningful inflection point: it marked the first quarter in which the entire company returned to organic sales growth, building on the stabilization seen in the prior two quarters. In my view, this report matters because it tests whether Avantor's cost and commercial initiatives can convert a stronger demand environment into durable, profitable growth. The results also carry broader read-through for the life sciences supply chain, offering a window into research funding, pharma and biotech spending, and lab activity across global end markets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Avantor (AVTR) posted net sales of $1.698 billion, a 4.6% reported increase and 5.2% organic growth from the prior-year period. Revenue exceeded analysts' consensus estimate of approximately $1.64 billion. Adjusted EPS of $0.22 topped the $0.21 consensus, while GAAP diluted EPS was $0.30, compared with a net loss of $711.8 million in the year-ago quarter that included a large impairment charge.
Segment performance was broad-based. VWR Distribution & Services generated $1.234 billion in revenue, up 5.8% organically, reflecting stronger commercial execution and healthier end markets. Bioscience & Medtech Products (BMP) returned to growth with revenue of $464.5 million, up 3.6% organically, ahead of management's expectations. Adjusted EBITDA was roughly $257 million, a 15.1% margin. The company generated $156 million in free cash flow, or $169 million excluding cash restructuring costs, and reduced its adjusted net leverage ratio to 3.1 times from 3.3 times in the prior quarter.
Market Reaction and Investor Sentiment
The market's response to Avantor's (AVTR) third-quarter results was measured. Although the company beat consensus on both revenue and adjusted EPS and raised its full-year outlook, shares fell about 2.5% to around $16.71 in early trading. That pullback reflected lingering concerns about profitability: adjusted EBITDA declined year over year, and consolidated margins remain below historical levels as faster growth in the lower-margin VWR distribution business weighs on the mix. With the stock having surged over the prior six months and trading near a 52-week high, some investors appeared to take profits even as the underlying results confirmed a genuine return to growth.
Forward Outlook and Key Factors to Monitor
Following this report, the focus shifts to whether Avantor (AVTR) can sustain its recovery momentum and translate revenue growth into margin expansion. Management raised full-year 2026 guidance, now expecting organic revenue growth of 0.75% to 1.25%, adjusted EPS of $0.81 to $0.83, and free cash flow of $525 million to $550 million.
Investors should watch several factors in the months ahead. First, the December 8, 2026 Investor Day will be a key catalyst, as management is expected to provide more detail on 2027 expectations and the longer-term trajectory of the Revival program. Second, margin trends matter: the company must absorb inflationary pressures and an unfavorable product mix while continuing targeted growth investments. Third, geographic demand is uneven, with the Americas and Asia performing well while Europe lags amid budget and funding pressures. From what I see, continued debt reduction could support the stock's valuation going forward.
Enhancing My Research with Tickeron’s AI Screener
In my own analysis, I often rely on Tickeron’s AI Screener to quickly filter stocks by technical patterns, fundamentals, and performance metrics. It helps surface relevant ideas and compare opportunities across sectors more efficiently than manual methods. This tool has become a practical part of refining watchlists for situations like the one with AVTR.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for AVTR turns positive, indicating new upward trend
AVTR saw its Momentum Indicator move above the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 61 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for AVTR just turned positive on October 15, 2026. Looking at past instances where AVTR's MACD turned positive, the stock continued to rise in 28 of 45 cases over the following month. The odds of a continued upward trend are 62%.
Following a +5.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVTR advanced for three days, in 172 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 112 of 174 cases where AVTR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVTR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
AVTR broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.058) is normal, around the industry mean (4.942). P/E Ratio (-20.153) is within average values for comparable stocks, (37.224). Projected Growth (PEG Ratio) (0.840) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.614) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. AVTR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of laboratory chemicals
Industry PharmaceuticalsOther
Advertisement